Zydus receives final approval from USFDA for Bortezomib for Injection
NEW DELHI: Zydus Lifesciences Ltd has announced that it has received final approval from the United States Food and Drug Administration (USFDA) to market Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial (USRLD: Velcade).
Bortezomib for Injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma.
The medication works by slowing or stopping the growth of cancer cells. The drug will be manufactured at Zydus Hospira. Velcade has a market size of USD 1,172mn (as per IQVIA MAT March 2022).